V E Epishin, M F Kalashnikova, N V Likhodey, I B Bondareva, A M Kaurova, M V Tulupova, N A Nikolaev, V V Fadeev
Background: Poor adherence to treatment among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) hinders the effective use of antidiabetic agents and the achievement of optimal glycemic control, reducing their quality of life and outcomes. Assessing adherence to treatment using a questionnaire can help identify and eliminate factors and barriers that negatively affect adherence to medical recommendations and satisfaction with treatment.
Aim: To conduct linguistic and cultural adaptation of the 12-item Medication Adherence Scale (MAS-12) questionnaire and evaluate the psychometric properties of the Russian version of the MAS-12 questionnaire among patients suffering from T1DM and T2DM.
Materials and methods: A survey of 198 patients with T1DM and T2DM was carried out, including self-completion of the MAS-12 questionnaire in Russian. Average age: 47.1±18.62 years, proportion of women - 76%. Average duration of the disease: 13.08±10.05 years. The construct validity of the MAS-12 questionnaire was assessed using confirmatory factor analysis. As an external criterion for assessing convergent validity, the KOP-25 method was used - the Russian Questionnaire for Quantitative Assessment of Treatment Adherence (KOP-25). Reliability of the MAS-12 was assessed using Cronbach's α internal consistency and participant retest after 1 to 4 months.
Results: The factor structure of the MAS-12 questionnaire is reproduced for the first time on a Russian sample of patients with diabetes. Recommended fit indicators for the measurement model (CFI=0.983, RMSEA=0.049, TLI=0.968) were achieved by excluding two items (9 and 12) that did not demonstrate statistically significant contributions to their respective subscales. The internal consistency of the subscales (α ϵ [0.522; 0.857]) and the questionnaire as a whole (α=0.766) was assessed as sufficient. Significant correlations of the adapted methodology and its subscales with the scales of the KOP-25 questionnaire were obtained. The closest connections (r ϵ [0.333; 0.431], p<0.010) are observed with the COP-25 scales related to drug therapy, which indicates good external validity of the adapted methodology.
Conclusion: The Russian version of the MAS-12 questionnaire "Questionnaire for assessing adherence to medication treatment" (PML-10), consisting of 10 questions, has good psychometric properties, is a valid and reliable tool for assessing medication adherence among patients with T1DM and T2DM and can be recommended for use in clinical practice, including for monitoring treatment adherence in Russia.
{"title":"[Adaptation of the 12-item medication adherence scale ( the Questionnaire for assessment of adherence to Medication) on a Russian-speaking sample of patients with type 1 and type 2 diabetes mellitus].","authors":"V E Epishin, M F Kalashnikova, N V Likhodey, I B Bondareva, A M Kaurova, M V Tulupova, N A Nikolaev, V V Fadeev","doi":"10.14341/probl13372","DOIUrl":"10.14341/probl13372","url":null,"abstract":"<p><strong>Background: </strong>Poor adherence to treatment among patients with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) hinders the effective use of antidiabetic agents and the achievement of optimal glycemic control, reducing their quality of life and outcomes. Assessing adherence to treatment using a questionnaire can help identify and eliminate factors and barriers that negatively affect adherence to medical recommendations and satisfaction with treatment.</p><p><strong>Aim: </strong>To conduct linguistic and cultural adaptation of the 12-item Medication Adherence Scale (MAS-12) questionnaire and evaluate the psychometric properties of the Russian version of the MAS-12 questionnaire among patients suffering from T1DM and T2DM.</p><p><strong>Materials and methods: </strong>A survey of 198 patients with T1DM and T2DM was carried out, including self-completion of the MAS-12 questionnaire in Russian. Average age: 47.1±18.62 years, proportion of women - 76%. Average duration of the disease: 13.08±10.05 years. The construct validity of the MAS-12 questionnaire was assessed using confirmatory factor analysis. As an external criterion for assessing convergent validity, the KOP-25 method was used - the Russian Questionnaire for Quantitative Assessment of Treatment Adherence (KOP-25). Reliability of the MAS-12 was assessed using Cronbach's α internal consistency and participant retest after 1 to 4 months.</p><p><strong>Results: </strong>The factor structure of the MAS-12 questionnaire is reproduced for the first time on a Russian sample of patients with diabetes. Recommended fit indicators for the measurement model (CFI=0.983, RMSEA=0.049, TLI=0.968) were achieved by excluding two items (9 and 12) that did not demonstrate statistically significant contributions to their respective subscales. The internal consistency of the subscales (α ϵ [0.522; 0.857]) and the questionnaire as a whole (α=0.766) was assessed as sufficient. Significant correlations of the adapted methodology and its subscales with the scales of the KOP-25 questionnaire were obtained. The closest connections (r ϵ [0.333; 0.431], p<0.010) are observed with the COP-25 scales related to drug therapy, which indicates good external validity of the adapted methodology.</p><p><strong>Conclusion: </strong>The Russian version of the MAS-12 questionnaire \"Questionnaire for assessing adherence to medication treatment\" (PML-10), consisting of 10 questions, has good psychometric properties, is a valid and reliable tool for assessing medication adherence among patients with T1DM and T2DM and can be recommended for use in clinical practice, including for monitoring treatment adherence in Russia.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"32-43"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D N Kostyleva, P M Khandaeva, A M Lapshina, E G Przhialkovskaya, Zh E Belaya, А Yu Grigoriev, G A Mel'nichenko
According to numerous studies, the most common pituitary tumors are prolactinomas, reaching 60% of all clinically significant adenomas, the next in order are non-functional pituitary adenomas, somatotropinomas, corticotropinomas and thyrotropinomas. Plurigormonal tumors occur in less than 1% of all pituitary adenomas. The most common form of mixed secretion adenoma in this patient population, derived from the Pit-1 cell line, produces various combinations of hormones: growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH). This article presents a patient with a plurihormonal two-component pituitary macroadenoma with a rare and exceptional combination of secreted hormones - GH / adrenocorticotropic hormone (ACTH) / TSH / follicle-stimulating hormone (FSH) / luteinizing hormone (LH) with minimal nonspecific clinical manifestations such as diabetes mellitus and poorly controlled arterial hypertension.
{"title":"[Clinical case of plurihormonal pituitary adenoma (STH/ACTH/TSH/FSH/LH-secreting), diagnostic pitfalls].","authors":"D N Kostyleva, P M Khandaeva, A M Lapshina, E G Przhialkovskaya, Zh E Belaya, А Yu Grigoriev, G A Mel'nichenko","doi":"10.14341/probl13349","DOIUrl":"10.14341/probl13349","url":null,"abstract":"<p><p>According to numerous studies, the most common pituitary tumors are prolactinomas, reaching 60% of all clinically significant adenomas, the next in order are non-functional pituitary adenomas, somatotropinomas, corticotropinomas and thyrotropinomas. Plurigormonal tumors occur in less than 1% of all pituitary adenomas. The most common form of mixed secretion adenoma in this patient population, derived from the Pit-1 cell line, produces various combinations of hormones: growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH). This article presents a patient with a plurihormonal two-component pituitary macroadenoma with a rare and exceptional combination of secreted hormones - GH / adrenocorticotropic hormone (ACTH) / TSH / follicle-stimulating hormone (FSH) / luteinizing hormone (LH) with minimal nonspecific clinical manifestations such as diabetes mellitus and poorly controlled arterial hypertension.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"24-31"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551793/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
O К Vikulova, A V Zheleznyakova, A A Serkov, M A Isakov, G R Vagapova, F V Valeeva, N P Trubicina, O G Melnikova, V K Aleksandrova, N B Smirnova, D N Egorova, E V Artemova, K V Sorokina, M V Shestakova, N G Mokrysheva, I I Dedov
Background: Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.
Aim: to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.
Materials and methods: a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.
Results: Clinical characteristics of patients with T1DM/T2DM: age - 49.2/64.5 years, duration of DM - 22/11 years, proportion of women - 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren't statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.
Conclusion: There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.
{"title":"[Multiplex analysis of post-Covid cardiorenal complications in patients with type 1 and type 2 diabetes mellitus according to the mobile diagnostic and treatment center (Diamobil)].","authors":"O К Vikulova, A V Zheleznyakova, A A Serkov, M A Isakov, G R Vagapova, F V Valeeva, N P Trubicina, O G Melnikova, V K Aleksandrova, N B Smirnova, D N Egorova, E V Artemova, K V Sorokina, M V Shestakova, N G Mokrysheva, I I Dedov","doi":"10.14341/probl13426","DOIUrl":"10.14341/probl13426","url":null,"abstract":"<p><strong>Background: </strong>Patients with diabetes mellitus (DM) are at risk for a higher incidence and severity of COVID-19, as well as its adverse outcomes, including post-Covid syndrome.</p><p><strong>Aim: </strong>to assess the incidence of cardiorenal complications in patients with type 1 and type 2 diabetes (T1DM/T2DM) who have had COVID-19, and to analyze the structure and severity of disorders according to examination data at the Diamobil mobile medical diagnostic and treatment center.</p><p><strong>Materials and methods: </strong>a cohort of T1DM and T2DM patients examined in Diamobil (n=318), with a confirmed anamnesis of COVID-19 (n=236). The time interval between COVID-19 and the visit to Diamobil was 8.7/8.2 months for T1DM/T2DM. The parameters of the last visit before COVID-19 recorded in the Federal Register of Diabetes (FRD) were used as initial data.</p><p><strong>Results: </strong>Clinical characteristics of patients with T1DM/T2DM: age - 49.2/64.5 years, duration of DM - 22/11 years, proportion of women - 64/73%, respectively. After analysis the data from visits before and after COVID-19 there weren't statistically significant differences in HbA1c levels for both types of DM (before 9.0/8.3%; after 8.4/8.2%, respectively), there was the intensification of glucose lowering therapy (the proportion of patients with T2DM on 2 and 3 component therapy increased by 4.3% and 1.6%, the proportion of patients on insulin therapy by 16%). After COVID-19, there was a statistically significant decrease in glomerular filtration rate (GFR) in T1DM from 88.1 to 62 ml/min/1.73 m2; with T2DM from 74.7 to 54.1 ml/min/1.73 m2. When assessing acute diabetic complications, there was an increase in the frequency of coma in T1DM by 1.5 times, severe hypoglycemia in T1DM by 3 times, and in T2DM by 1.7 times. Analysis of the frequency of cardiorenal complications before and after COVID-19 showed a total increase of 8.5% in T1DM, by 13.2% in T2DM, of which myocardial infarction, ischemic heart disease, and CHF increased in T1DM in the range from 1.5 to 5 times, with T2DM by 1.3 times, the frequency of CKD with T1DM by 1.5 times, with T2DM by 5.6 times.</p><p><strong>Conclusion: </strong>There was a decline of kidney filtration function (decrease in GFR) and an increase in the frequency of cardiovascular complications in both types of diabetes in post-Covid period while patients achieved a stable HbA1c levels by intensifying therapy during the COVID-19 infection. This fact reflects combined damage to the kidney and cardiovascular system as a part of the post-Covid syndrome and determines a key set of measures for the development of preventive strategies.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"65-74"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
L K Dzeranova, E A Pigarova, S Yu Vorotnikova, A A Voznesenskaya
Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus. The above clinical case describes the development of hypophysitis in a pregnant woman with a predominant lesion of the posterior pituitary gland and an outcome in diabetes insipidus, which persists 6 years after pregnancy and childbirth. In the article some aspects of the differential diagnosis of diabetes insipidus in pregnant women, as well as instrumental diagnosis and treatment approaches of hypophysitis are discussed.
{"title":"[Hypophisitis in pregnant women with persistent diabetes insipidus in the outcome].","authors":"L K Dzeranova, E A Pigarova, S Yu Vorotnikova, A A Voznesenskaya","doi":"10.14341/probl13384","DOIUrl":"10.14341/probl13384","url":null,"abstract":"<p><p>Autoimmune/lymphocytic hypophysitis is one of the rare causes of central diabetes insipidus in adults and is most common among women in the second or third trimester of pregnancy. Numerous studies have shown that lymphocytic hypophysitis is characterized by a very variable clinical signs with the development of neurological symptoms, visual disturbances and hypopituitarism with partial or complete loss of pituitary function, as well as a number of features in magnetic resonance imaging (MRI). Isolated lymphocytic indibuloneurohypophysitis occurs in fewer cases and involves the posterior lobe and stalk of the pituitary gland with a clinical presentation of diabetes insipidus. The above clinical case describes the development of hypophysitis in a pregnant woman with a predominant lesion of the posterior pituitary gland and an outcome in diabetes insipidus, which persists 6 years after pregnancy and childbirth. In the article some aspects of the differential diagnosis of diabetes insipidus in pregnant women, as well as instrumental diagnosis and treatment approaches of hypophysitis are discussed.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"15-23"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551802/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M V Yaroslavceva, O N Bondarenko, Ya A El-Taravi, S T Magerramova, E A Pigarova, I N Ulyanova, G R Galstyan
Diabetic neuropathy is one of the most common diabetes mellitus complications associated with mediocalcinosis of the lower extremities, a significant decrease in feet bone mineral density, and a high incidence of cardiovascular disease. In most cases, calcium-phosphorus metabolism changes occur in patients with diabetic neuroarthropathy, or Charcot foot, when we can observe feet local osteoporosis, which in 90% of cases associated with a vessel's calcification of the lower extremities in the majority of diabetes population. A large number of studies presented literature have demonstrated that patients with Charcot foot can have accelerated bone metabolism and increased bone resorption. Patients with Charcot foot often have crucial abnormalities in the calcium-phosphorus parameters, bone metabolism, and levels of vitamin D and its metabolites. In addition, the duration of diabetes mellitus, the degree of its compensation widely affects the development of its micro- and macrovascular complications, which could also accelerate the development of mineral and bone disorders in these types of patients. Multifactorial pathogenesis of these disorders complicates the management of patients with a long and complicated course of diabetes mellitus. This review discusses the peculiarities of vitamin D metabolism, the importance of timely diagnosis in phosphorus-calcium disorders, and the specifics of therapy in these patients. Special attention is paid to the timely diagnosis of the Charcot's foots acute stage based on the bone marrow edema by MRI evaluation and the possibility of reducing the immobilization period.
糖尿病神经病变是最常见的糖尿病并发症之一,与下肢中钙化、足部骨矿密度明显降低和心血管疾病的高发病率有关。在大多数情况下,钙磷代谢变化发生在糖尿病神经性关节病或夏科足患者身上,此时我们可以观察到足部局部骨质疏松症,在 90% 的病例中,大多数糖尿病患者的下肢与血管钙化有关。大量研究文献表明,Charcot 足患者的骨代谢加速,骨吸收增加。夏科脚患者通常在钙磷参数、骨代谢、维生素 D 及其代谢物水平方面存在严重异常。此外,糖尿病病程的长短、糖尿病的代偿程度会广泛影响其微血管和大血管并发症的发展,这也会加速这类患者矿物质和骨骼紊乱的发展。这些疾病的多因素致病机理使得对病程长、病情复杂的糖尿病患者的治疗变得更加复杂。本综述讨论了维生素 D 代谢的特殊性、及时诊断磷钙紊乱的重要性以及这些患者的具体治疗方法。其中特别关注通过磁共振成像评估骨髓水肿,及时诊断沙氏足急性期,以及缩短固定期的可能性。
{"title":"[Etiopathogenetic features of bone metabolism in patients with diabetes mellitus and Charcot foot].","authors":"M V Yaroslavceva, O N Bondarenko, Ya A El-Taravi, S T Magerramova, E A Pigarova, I N Ulyanova, G R Galstyan","doi":"10.14341/probl13362","DOIUrl":"10.14341/probl13362","url":null,"abstract":"<p><p>Diabetic neuropathy is one of the most common diabetes mellitus complications associated with mediocalcinosis of the lower extremities, a significant decrease in feet bone mineral density, and a high incidence of cardiovascular disease. In most cases, calcium-phosphorus metabolism changes occur in patients with diabetic neuroarthropathy, or Charcot foot, when we can observe feet local osteoporosis, which in 90% of cases associated with a vessel's calcification of the lower extremities in the majority of diabetes population. A large number of studies presented literature have demonstrated that patients with Charcot foot can have accelerated bone metabolism and increased bone resorption. Patients with Charcot foot often have crucial abnormalities in the calcium-phosphorus parameters, bone metabolism, and levels of vitamin D and its metabolites. In addition, the duration of diabetes mellitus, the degree of its compensation widely affects the development of its micro- and macrovascular complications, which could also accelerate the development of mineral and bone disorders in these types of patients. Multifactorial pathogenesis of these disorders complicates the management of patients with a long and complicated course of diabetes mellitus. This review discusses the peculiarities of vitamin D metabolism, the importance of timely diagnosis in phosphorus-calcium disorders, and the specifics of therapy in these patients. Special attention is paid to the timely diagnosis of the Charcot's foots acute stage based on the bone marrow edema by MRI evaluation and the possibility of reducing the immobilization period.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"57-64"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551796/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A V Simanenkova, O S Fuks, N V Timkina, D A Sufieva, O V Kirik, D E Korzhevskii, T D Vlasov, T L Karonova
<p><strong>Background: </strong>Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients' disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.</p><p><strong>Aim: </strong>To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.</p><p><strong>Materials and methods: </strong>The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the "MET" group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the "MET+EMPA" group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.</p><p><strong>Results: </strong>Both in the "MET+EMPA" and the "MET" groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the "MET" group, 3.22 (2.94; 3.54) ng/ml in the "MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.</p><p><strong>Conclusion: </strong>Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifeste
{"title":"[Highly selective sodium-glucose co-transporter type 2 inhibitor empagliflozin as means of brain protection in conditions of chronic brain dyscirculation].","authors":"A V Simanenkova, O S Fuks, N V Timkina, D A Sufieva, O V Kirik, D E Korzhevskii, T D Vlasov, T L Karonova","doi":"10.14341/probl13336","DOIUrl":"10.14341/probl13336","url":null,"abstract":"<p><strong>Background: </strong>Chronic brain dyscirculation is one of the frequent type 2 diabetes mellitus (DM) complications and leads to patients' disability. Sodium-glucose co-transporter type 2 inhibitors (SGLT-2i) have been proven to have advantages for cardiovascular system, but their effect on the central nervous system (CNS) has not been studied enough.</p><p><strong>Aim: </strong>To study empagliflozin effect on CNS damage functional and laboratory parameters in patients with type 2 DM and, under experimental conditions, to investigate the mechanisms of the drug neurotropic effect.</p><p><strong>Materials and methods: </strong>The clinical part of the study included patients with type 2 DM on metformin monotherapy (n=39). Patients with a target glycated hemoglobin level formed the \"MET\" group (n=19), in patients with a non-target glycated hemoglobin level empagliflozin was co-administered for the following 6 months (the \"MET+EMPA\" group, n=20). Healthy volunteers comprised the control group (n=16). The cognitive status and neuron-specific enolase (NSE) and neurofilament light chains (NLC) concentration were studied. DM was modeled in rats, thereafter the rats were treated with empagliflozin for 8 weeks. Microglia activation was assessed using anti-Iba-1 antibodies and morphological changes in neurons when stained by the Nissl method.</p><p><strong>Results: </strong>Both in the \"MET+EMPA\" and the \"MET\" groups cognitive deficits were observed, according to the Montreal Cognitive Assessment (MOCA) (24.0 (23.0; 27.0) and 25.0 (21.0; 27.0) points) and the Mini-Mental State Examination (MMSE) (23.75 (23.0; 27.0) and 25.0 (21.0; 27.0) points). Empagliflozin therapy led to the cognitive status normalization after 6 months (26.5 (24.0; 27.0) points according to the MOCA scale and 27.5 (24.0; 28.0) points according to the MMSE). Initially, all patients had a significant increase of NSE (3.60 (2.66; 3.76) ng/ml in the \"MET\" group, 3.22 (2.94; 3.54) ng/ml in the \"MET+EMPA» group, 2.72 (2.13; 2.72) ng/ml in the «Control» group) and NLC (4.50 (3.31; 5.56) ng/ml in the «MET» group, 5, 25 (3.75; 6.25) ng/ml in the «MET+EMPA» group comparing with 3.50 (2.25; 3.50) ng/ml in the «Control» group). Empagliflozin therapy led to a significant decrease in NLC already after 3 months (3.80 (3.25; 3.87) ng/ml), without significant influence on the NSE level. In the experiment, DM was characterized by an increased number of activated microgliocytes and destructured neurons and a decreased number of neurons with a normal structure. Empagliflozin therapy was accompanied by a decrease in the number of immunopositive microgliocytes in the CA1 zone of the hippocampus and an increase in the number of structured neurons.</p><p><strong>Conclusion: </strong>Type 2 diabetes mellitus is characterized by functional and biochemical changes in the central nervous system even under satisfactory glycemic control. Therapy with empagliflozin has a neuroprotective effect, manifeste","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 4","pages":"44-56"},"PeriodicalIF":0.0,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A Chevais, M M Gadzhimuradova, D G Beltsevich, A N Romanova, K Sh Begova, H V Bagirova, A K Ebzeeva, G A Melnichenko
Steroid hormones take an active part in a whole complex of physiological processes that are fundamental for the normal development and functioning of the human body. In the bloodstream steroid hormones are bind with specific transport proteins, in particular with transcortin. The matter of changes in hormone-protein complex in various conditions were actively studied in the second half of the twentieth century, but currently this issue has been taken a back seat by the development of high-precision diagnostic methods of steroid hormones determining. This literature review presents accumulated data on the physicochemical properties of transcortin, genetic factors affecting its synthesis and secretion. Published data on its physiological significance in the human body are analyzed in detail within the framework of not only the "free hormone" hypothesis, but also the reservoir hypothesis. Research results have shown that the synthesis of transcortin has been detected in some extrahepatic tissues, including the adrenal glands, however, its role is unknown.
{"title":"[The functional role and properties of transcortin in the human body].","authors":"A Chevais, M M Gadzhimuradova, D G Beltsevich, A N Romanova, K Sh Begova, H V Bagirova, A K Ebzeeva, G A Melnichenko","doi":"10.14341/probl13482","DOIUrl":"10.14341/probl13482","url":null,"abstract":"<p><p>Steroid hormones take an active part in a whole complex of physiological processes that are fundamental for the normal development and functioning of the human body. In the bloodstream steroid hormones are bind with specific transport proteins, in particular with transcortin. The matter of changes in hormone-protein complex in various conditions were actively studied in the second half of the twentieth century, but currently this issue has been taken a back seat by the development of high-precision diagnostic methods of steroid hormones determining. This literature review presents accumulated data on the physicochemical properties of transcortin, genetic factors affecting its synthesis and secretion. Published data on its physiological significance in the human body are analyzed in detail within the framework of not only the \"free hormone\" hypothesis, but also the reservoir hypothesis. Research results have shown that the synthesis of transcortin has been detected in some extrahepatic tissues, including the adrenal glands, however, its role is unknown.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 6","pages":"27-34"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Y S Absatarova, Y S Evseeva, E N Andreeva, Z T Zuraeva, E V Sheremetyeva, O R Grigoryan, R K Mikheev
Amenorrhea is a common symptom of a whole range of nosologies among women of reproductive age, which can accompany any endocrinopathy in the stage of decompensation. In all the diversity of various links in the pathogenesis of reproductive disorders, the problem of immunopathology remains a little aside, however, the significance of these disorders is underestimated. This publication provides an overview of immune system abnormalities in a women with amenorrhea. As is known, in polycystic ovary syndrome (PCOS) and premature ovarian insufficiency (POI), one of the clinical manifestations is amenorrhea. On the one hand, these nosologies differ significantly from each other in etiology, pathogenesis and approaches to therapy, and on the other hand, they have a common similarity, manifested by immunological disorders. The article provides information about the immune status of patients with PCOS and POI. Works devoted to various disorders in the immune system, pathologies of humoral and cellular immunity, which in the future may serve as the key to the development of new and non-standard methods of treating such socially significant diseases, are analyzed. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The choice of sources was prioritized for the period from 2018 to 2024.
{"title":"[Immunological status in patients with amenorrhea (literature review)].","authors":"Y S Absatarova, Y S Evseeva, E N Andreeva, Z T Zuraeva, E V Sheremetyeva, O R Grigoryan, R K Mikheev","doi":"10.14341/probl13456","DOIUrl":"10.14341/probl13456","url":null,"abstract":"<p><p>Amenorrhea is a common symptom of a whole range of nosologies among women of reproductive age, which can accompany any endocrinopathy in the stage of decompensation. In all the diversity of various links in the pathogenesis of reproductive disorders, the problem of immunopathology remains a little aside, however, the significance of these disorders is underestimated. This publication provides an overview of immune system abnormalities in a women with amenorrhea. As is known, in polycystic ovary syndrome (PCOS) and premature ovarian insufficiency (POI), one of the clinical manifestations is amenorrhea. On the one hand, these nosologies differ significantly from each other in etiology, pathogenesis and approaches to therapy, and on the other hand, they have a common similarity, manifested by immunological disorders. The article provides information about the immune status of patients with PCOS and POI. Works devoted to various disorders in the immune system, pathologies of humoral and cellular immunity, which in the future may serve as the key to the development of new and non-standard methods of treating such socially significant diseases, are analyzed. Literature search was carried out in national (eLibrary, CyberLeninka.ru) and international (PubMed, Cochrane Library) databases in Russian and English. The choice of sources was prioritized for the period from 2018 to 2024.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 6","pages":"118-126"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775678/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
S V Sumina, E A Pigarova, L K Dzeranova, A G Kuzmin
The Endocrinology Reserch Centre is proud not only of its achievements in the area of personalized approach to the examination and treatment of patients in accordance with the principles of evidence-based medicine, the use of modern diagnostic and treatment technologies, but also of its rich history of training scientific and medical personnel. For many years the Center has been attracting the best and most talented graduates of higher medical institutions, becoming the "alma mater" for young doctors - endocrinologists, pediatric endocrinologists and nutritionists. Specialists, graduates of NMRC, make a significant contribution to the development of medicine, conducting research, creating innovative methods of treatment and helping patients not only in our country, but also abroad. However, the State Research Center of the Russian Federation FGBU «NMRC Endocrinology» is famous not only for its high-quality and comprehensive training, but also for its experienced, dedicated teaching staff, giving students unique opportunities for professional growth. The purpose of this article is to reflect the most important milestones in the development of education at NMIC Endocrinology, which began its formation more than a century ago, during the most difficult period of transition for our country.
{"title":"[The history of the institute of higher and additional professional education of the Endocrinology Reserch Centre].","authors":"S V Sumina, E A Pigarova, L K Dzeranova, A G Kuzmin","doi":"10.14341/probl13470","DOIUrl":"10.14341/probl13470","url":null,"abstract":"<p><p>The Endocrinology Reserch Centre is proud not only of its achievements in the area of personalized approach to the examination and treatment of patients in accordance with the principles of evidence-based medicine, the use of modern diagnostic and treatment technologies, but also of its rich history of training scientific and medical personnel. For many years the Center has been attracting the best and most talented graduates of higher medical institutions, becoming the \"alma mater\" for young doctors - endocrinologists, pediatric endocrinologists and nutritionists. Specialists, graduates of NMRC, make a significant contribution to the development of medicine, conducting research, creating innovative methods of treatment and helping patients not only in our country, but also abroad. However, the State Research Center of the Russian Federation FGBU «NMRC Endocrinology» is famous not only for its high-quality and comprehensive training, but also for its experienced, dedicated teaching staff, giving students unique opportunities for professional growth. The purpose of this article is to reflect the most important milestones in the development of education at NMIC Endocrinology, which began its formation more than a century ago, during the most difficult period of transition for our country.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"70 3","pages":"4-8"},"PeriodicalIF":0.0,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141790813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N A Mazerkina, S K Gorelyshev, A N Savateev, N A Strebkova, A L Kalinin
This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed. As a result of treatment, GH deficiency and secondary hypothyroidism developed. At age 9 years, signs of puberty appeared. Growth rate remained satisfactory until the age of 14 years. At the age of 14 growth rate slowed down, which was the reason for appointment. Upon examination, the bone age was 16 years and the projected final height without therapy was 162 cm. Given the poor growth prognosis, IA anastrozole in combination with GH was prescribed. During two years of therapy the growth gain amounted to 12.5 cm. This observation demonstrates that normal growth rates in patients with CP do not indicate preserved somatotropic function of the pituitary gland. With preserved sexual function, early or premature puberty may be observed. In such cases, IA can be prescribed in addition to GH - these are medications that inhibit the closure of growth. GH therapy in combination with IA is highly effective and safe in patients with GH deficiency after treatment of KF during puberty and allows to achieve good growth parameters.
{"title":"[First experience using an aromatase inhibitor in combination with growth hormone to improve growth prognosis in a 14-year-old boy with growth hormone deficiency after treatment of craniopharyngioma. A case-report].","authors":"N A Mazerkina, S K Gorelyshev, A N Savateev, N A Strebkova, A L Kalinin","doi":"10.14341/probl13446","DOIUrl":"10.14341/probl13446","url":null,"abstract":"<p><p>This article describes the first experience of successful use of growth hormone (GH) in combination with an aromatase inhibitor (AI), in a 14-year-old boy. At the age of 7, he presented with headaches, nausea and vomiting, and MRI revealed a craniopharyngioma (CP). An Ommaya system was implanted, and radiation therapy was performed. As a result of treatment, GH deficiency and secondary hypothyroidism developed. At age 9 years, signs of puberty appeared. Growth rate remained satisfactory until the age of 14 years. At the age of 14 growth rate slowed down, which was the reason for appointment. Upon examination, the bone age was 16 years and the projected final height without therapy was 162 cm. Given the poor growth prognosis, IA anastrozole in combination with GH was prescribed. During two years of therapy the growth gain amounted to 12.5 cm. This observation demonstrates that normal growth rates in patients with CP do not indicate preserved somatotropic function of the pituitary gland. With preserved sexual function, early or premature puberty may be observed. In such cases, IA can be prescribed in addition to GH - these are medications that inhibit the closure of growth. GH therapy in combination with IA is highly effective and safe in patients with GH deficiency after treatment of KF during puberty and allows to achieve good growth parameters.</p>","PeriodicalId":101419,"journal":{"name":"Problemy endokrinologii","volume":"71 1","pages":"66-71"},"PeriodicalIF":0.0,"publicationDate":"2024-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11931461/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143635060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}